Top Reddit ShortSqueeze Mentions This Weekend: TBLT, GME, BBBY, GOVX, BBIG, XELA, KPLT, EVFM, CHWA, AVCT
$AVCT
$BBBY
$BBIG
$CHWA
EDP Services
Technology
Other Specialty Stores
Consumer Discretionary
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/13/2024 | $9.00 | Equal-Weight | Stephens | |
| 11/11/2024 | $15.00 | Buy | Alliance Global Partners | |
| 7/16/2024 | $20.00 | Buy | ROTH MKM | |
| 6/8/2023 | $6.50 → $6.20 | Underperform | Wedbush | |
| 2/7/2023 | Hold → Sell | Odeon | ||
| 9/30/2022 | $7.50 | Sell → Hold | Odeon | |
| 9/1/2022 | Mkt Perform → Underperform | Raymond James | ||
| 8/18/2022 | $5.00 | Neutral → Underperform | Wedbush |
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
Eight Consecutive Quarters of Year-Over-Year Gross Originations Growth Expecting A Strong Holiday SeasonUpdates Full Year 2024 Gross Originations Outlook PLANO, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Katapult Holdings, Inc. ("Katapult" or the "Company") (NASDAQ:KPLT), an e-commerce-focused financial technology company, today reported its financial results for the third quarter ended September 30, 2024. "We are continuing to grow across key financial and operating metrics including gross originations and revenue, and we believe we are laying the foundation for the long-term success of Katapult," said Orlando Zayas, CEO of Katapult. "As we have grown the business, we've also meaning
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL). Based on the interim analysis of immune responses from the patients enrolled to date, the DSMB determined that, while the mRNA control arm of the study failed to meet the prede
GRAPEVINE, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today announced that Nat Turner, Chairman and CEO of Collectors Holdings, Inc., has been appointed to the Company's Board of Directors. Contact GameStop Investor [email protected]
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,
GRAPEVINE, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today announced that Nat Turner, Chairman and CEO of Collectors Holdings, Inc., has been appointed to the Company's Board of Directors. Contact GameStop Investor [email protected]
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice
Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Lance Rosenzweig as the Company's permanent Chief Executive Officer ("CEO"), effective immediately. The Company's Board of Directors (the "Board") carried out an extensive CEO search process that was supported by a nationally recognized executive recruiting firm and included both internal and external candidates. After assessing Mr. Rosenzweig's considerable contributions as interim CEO and his track record of value creation at Pitney Bowes and at other co
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - Toughbuilt Industries, Inc (0001668370) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
SC 13G/A - Toughbuilt Industries, Inc (0001668370) (Subject)
SC 13G/A - Katapult Holdings, Inc. (0001785424) (Subject)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
4 - Exela Technologies, Inc. (0001620179) (Issuer)
4 - Exela Technologies, Inc. (0001620179) (Issuer)
4 - Exela Technologies, Inc. (0001620179) (Issuer)
Investors with a lot of money to spend have taken a bearish stance on GameStop (NYSE:GME). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GME, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 uncommon options trades for GameStop. This isn't normal. The overall sentiment of these big-money traders is split between 4% bullish and 90%, bearish. Out of all of the special optio
EF Hutton analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $18.
Stephens initiated coverage of Katapult Group with a rating of Equal-Weight and set a new price target of $9.00
Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
8-K - GameStop Corp. (0001326380) (Filer)
10-Q - Exela Technologies, Inc. (0001620179) (Filer)